+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Autoimmune Disease Diagnostics Market (2021-2026) by Product Type, Diagnostic Tests, Diseases, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon


  • 186 Pages
  • April 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5392897
The Global Autoimmune Disease Diagnostics Market is estimated to be USD 4.98 Bn in 2021 and is expected to reach USD 7.84 Bn by 2026, growing at a CAGR of 9.5%.

Market Dynamics

The increasing prevalence of autoimmune diseases such as arthritis, inflammatory bowel disease, multiple sclerosis, diabetes type 1, etc. is the major factor increasing the autoimmune disease diagnostics market. The rising sedentary lifestyle leading to autoimmune diseases, growing healthcare expenditure, and increasing geriatric population have exhibited market growth. Furthermore, government initiatives in the healthcare sector and private companies increasing investment in research and development in autoimmune diseases are anticipated to create new opportunities for the market, globally.

However, the high cost of autoimmune disease diagnostics and low awareness in emerging countries is anticipated to hamper the market growth.

Market Segmentation

The Global Autoimmune Disease Diagnostics Market is segmented further based on Product Type, Diagnostic Tests, Diseases, and Geography.

By Product Type, the market is classified into consumables & assay kits, and instruments. Amongst all, the consumables & assay kits segment is estimated to hold the highest market share during the forecast period.

By Diagnostic Test, the market is classified as routine laboratory tests, inflammatory markers, autoantibodies and immunologic tests, and other tests. Amongst the two, the routine laboratory tests segment is estimated to hold the highest market share during the forecast period.

By Diseases, the market is classified as systemic autoimmune disease diagnostics, and localized autoimmune disease diagnostics. Amongst the two, the localized autoimmune disease diagnostics segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Thermo Fisher Scientific to Acquire QIAGEN N.V. a leading provider of life science and molecular diagnostic solutions having presence in around 25 countries. - 3rd March 2020.
2. Progentec launched a novel blood test - aiSLE™ DX Flare Risk Index laboratory test that can assess the likelihood of a systemic lupus erythematosus patient experiencing an immunologic disease flare in the ensuing 12 weeks. - 15th September 2020.

Company Profiles

Some of the companies covered in this report Thermo Fisher Scientific Inc, Progentec Diagnostics, Inc., Siemens AG, Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories, Inc, Grifols, S.A., etc.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?
  • The report offers a comprehensive evaluation of the Global Autoimmune Disease Diagnostics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains a competitive analysis using the Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Report Highlights:
  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Autoimmune Disease Diagnostics Market

What is the estimated value of the Global Autoimmune Disease Diagnostics Market?

The Global Autoimmune Disease Diagnostics Market was estimated to be valued at $4980 Million in 2021.

What is the growth rate of the Global Autoimmune Disease Diagnostics Market?

The growth rate of the Global Autoimmune Disease Diagnostics Market is 9.5%, with an estimated value of $7840 Million by 2026.

What is the forecasted size of the Global Autoimmune Disease Diagnostics Market?

The Global Autoimmune Disease Diagnostics Market is estimated to be worth $7840 Million by 2026.

Who are the key companies in the Global Autoimmune Disease Diagnostics Market?

Key companies in the Global Autoimmune Disease Diagnostics Market include A. Menarini Diagnostics S.r.l., Abbott Laboratories, AstraZeneca plc, Beckman Coulter Inc, Bio, Rad Laboratories, Inc, Danaher Corporation, Exagen Inc. and La Roche.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Increasing Prevalence of Autoimmune Diseases
4.1.2 Rising Online Diagnostic Centres and Laboratory Automation
4.1.3 High Number of Research in Autoimmune Diseases
4.2 Restraints
4.2.1 Stringent Government Regulation
4.2.2 High Cost of Reimbursement
4.3 Opportunities
4.3.1 Advancement in Biosensors Diagnosis
4.3.2 Growing Healthcare Sectors in Developing Countries
4.4 Challenges
4.4.1 Lack of Awareness of Autoimmune Disease in Emerging Diseases
4.4.2 Insufficient Skilled Professional
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Autoimmune Disease Diagnostics Market, By Product Type
6.1 Introduction
6.2 Consumables & Assay Kits
6.3 Instruments
7 Global Autoimmune Disease Diagnostics Market, By Diagnostic Tests
7.1 Introduction
7.2 Routine Laboratory Tests
7.2.1 Urinalysis
7.2.2 Others
7.3 Inflammatory Markers
7.3.1 Erythrocyte Sedimentation Rate (ESR)
7.3.2 C-Reactive Protein (CRP)
7.3.3 Others
7.4 Autoantibodies And Immunologic Tests
7.4.1 Enzyme-Linked Immunosorbent Assay (ELISA)
7.4.2 Antinuclear Antibody Tests
7.4.3 Others
7.5 Other Tests
8 Global Autoimmune Disease Diagnostics Market, By Diseases
8.1 Introduction
8.2 Systemic Autoimmune Disease Diagnostics
8.2.1 Systemic Lupus Erythematosus
8.2.2 Ankylosing Spondylitis
8.2.3 Rheumatoid Arthritis
8.2.4 Others
8.3 Localized Autoimmune Disease Diagnostics
8.3.1 Inflammatory Bowel Disease
8.3.2 Type 1 Diabetes
8.3.3 Thyroid
8.3.4 Others
9 Global Autoimmune Disease Diagnostics Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 South America
9.3.1 Brazil
9.3.2 Argentina
9.3.3 Chile
9.3.4 Colombia
9.4 Europe
9.4.1 UK
9.4.2 France
9.4.3 Germany
9.4.4 Italy
9.4.5 Spain
9.4.6 Netherlands
9.4.7 Sweden
9.4.8 Russia
9.4.9 Rest of Europe
9.5 Asia-Pacific
9.5.1 China
9.5.2 Japan
9.5.3 India
9.5.4 Indonesia
9.5.5 Malaysia
9.5.6 South Korea
9.5.7 Australia
9.5.8 Sri Lanka
9.5.9 Thailand
9.5.10 Rest of APAC
9.6 Middle-East and Africa
9.6.1 Qatar
9.6.2 Saudi Arabia
9.6.3 South Africa
9.6.4 United Arab Emirates
10 Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Strategic Initiatives
10.3.1 M&A and Investments
10.3.2 Partnerships and Collaborations
10.3.3 Product Developments and Improvements
11 Company Profiles
11.1 A. Menarini Diagnostics S.r.l.
11.2 Abbott Laboratories
11.3 AstraZeneca plc
11.4 Beckman Coulter Inc
11.5 Bio-Rad Laboratories, Inc
11.6 Danaher Corporation
11.7 Exagen Inc.
11.8 F. Hoffmann-La Roche
11.9 Grifols, S.A.
11.10 Hemagen Diagnostics Inc.
11.11 HTG Molecular Diagnostics, Inc
11.12 Inova Diagnostics Inc.
11.13 Novartis AG
11.14 Pfizer Inc
11.15 Progentec Diagnostics, Inc.
11.16 Seramun Diagnostica GmbH
11.17 Siemens AG
11.18 Thermo Fisher Scientific Inc
11.19 Trinity Biotech plc
11.20 Werfen
12 Appendix
12.1 Questionnaire

Companies Mentioned

  • A. Menarini Diagnostics S.r.l.
  • Abbott Laboratories
  • AstraZeneca plc
  • Beckman Coulter Inc
  • Bio-Rad Laboratories, Inc
  • Danaher Corporation
  • Exagen Inc.
  • F. Hoffmann-La Roche
  • Grifols, S.A.
  • Hemagen Diagnostics Inc.
  • HTG Molecular Diagnostics, Inc
  • Inova Diagnostics Inc.
  • Novartis AG
  • Pfizer Inc
  • Progentec Diagnostics, Inc.
  • Seramun Diagnostica GmbH
  • Siemens AG
  • Thermo Fisher Scientific Inc
  • Trinity Biotech plc
  • Werfen